- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Galecto GAAP EPS of -$0.62 misses by $0.23 | 2 | Seeking Alpha | ||
| Di | Damora Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| DAMORA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.05. | Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer | 2 | Insider Monkey | ||
| 04.05. | Damora Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.05. | Damora Therapeutics, Inc.: Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 23.04. | RBC initiates Damora Therapeutics stock at Outperform, $40 target | 1 | Investing.com | ||
| 20.04. | Damora Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | Damora Therapeutics, Inc.: Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 23.03. | Damora Therapeutics: Aktie legt nach Ernennung neuer CEO deutlich zu | 4 | Investing.com Deutsch | ||
| 23.03. | Damora Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 23.03. | Damora Therapeutics appoints Jennifer Jarrett as CEO | 1 | Seeking Alpha | ||
| 23.03. | Damora names Jennifer Jarrett CEO, adds two board members | 1 | Investing.com | ||
| 23.03. | Damora Therapeutics, Inc.: Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors | 692 | GlobeNewswire (Europe) | -- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter... ► Artikel lesen | |
| 20.03. | Leerink cuts Damora Therapeutics stock price target to $55 on timing | 2 | Investing.com | ||
| 20.03. | Damora Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 20.03. | Leerink senkt Kursziel für Damora Therapeutics wegen Zeitplan-Anpassungen | 1 | Investing.com Deutsch | ||
| 19.03. | Damora Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 10.03. | Galecto, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.03. | Galecto rebrands as Damora Therapeutics, begins Nasdaq trading | 3 | Investing.com | ||
| 09.03. | Galecto, Inc.: Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders | 297 | GlobeNewswire (Europe) | -- Company will trade on Nasdaq under trading symbol "DMRA" effective March 10, 2026 -- -- On track to submit IND or CTA for DMR-001 in mutant-calreticulin essential thrombocythemia and myelofibrosis... ► Artikel lesen |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,40 | -2,98 % | BioNTech-Krise vs. Emyria-Durchbruch? Warum Daten jetzt die Forschung schlagen | ||
| EVOTEC | 4,618 | -1,74 % | KURSRUTSCH bei Nel ASA und Evotec! KURSCHANCE bei HPQ Silicon! | Steht die Aktie von HPQ Silicon vor einer Neubewertung? Dafür gibt es jedenfalls gute Gründe. Die Hochleistungsbatterien haben erneut überzeugt. Damit könnte für Anwendungen in Drohnen, Verteidigung... ► Artikel lesen | |
| AMGEN | 282,15 | +0,46 % | Dividendenbekanntmachungen (15.05.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0514 EUR AF GRUPPEN ASA NO0003078107 6,5 NOK 0,6029 EUR AGCO CORPORATION US0010841023 0... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,400 | +1,15 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,309 | +3,00 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Grant of Restricted Stock Units | Montreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,405 | +1,00 % | Exosomen als Hoffnungsträger: Neuer Ansatz in der Glaukomtherapie | ||
| ABIVAX | 100,00 | +0,86 % | EQS-News: ABIVAX: Abivax Announces Results of its May 11, 2026 Annual General Meeting | EQS-News: ABIVAX
/ Key word(s): AGM/EGM
Abivax Announces Results of its May 11, 2026 Annual General Meeting
11.05.2026 / 22:05 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| IBIO | 1,274 | +0,39 % | iBio, Inc. - 10-Q, Quarterly Report | ||
| ARROWHEAD PHARMACEUTICALS | 65,68 | -0,45 % | Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events | Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
BofA Securities 2026 Healthcare Conference May 12-14, 2026
Type:... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 11,045 | +0,09 % | Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results | SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,580 | +10,49 % | Voyager Therapeutics, Inc.: Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026 | - VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON... ► Artikel lesen | |
| CYBIN | 4,035 | +0,50 % | Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs | Dr. Kramer's 25 years' of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and TORONTO... ► Artikel lesen | |
| CAPRICOR | 24,850 | +0,28 % | CAPRICOR THERAPEUTICS, INC. - 10-Q, Quarterly Report | ||
| HELIX BIOPHARMA | 0,680 | -2,86 % | Helix BioPharma Corp.: Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy | ||
| OPGEN | 1,568 | 0,00 % | CapForce Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB |
Das Unternehmen DAMORA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 24,640 Euro und damit +0,16 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DAMORA THERAPEUTICS INC finden Sie auf Wallstreet Online.